逆市四连涨！港股通创新药ETF（520880）开年强势反攻

Group 1 - The core viewpoint is that the Hong Kong Stock Connect innovative drug sector is experiencing a rebound, with the ETF (520880) showing a 2% increase and breaking above the 60-day moving average, indicating a potential reversal trend as of January 8 [1] - The Hang Seng Hong Kong Stock Connect Innovative Drug Select Index has undergone a significant adjustment, with a decline of over 24% since early September 2025, suggesting that the current period may be an optimal time for medium to long-term investment in core innovative drug assets [1] - The long-term logic of pharmaceutical innovation remains unchanged, with the recent positive market performance signaling good opportunities for innovative drugs and medical devices in 2026 [1] Group 2 - The Hong Kong Stock Connect innovative drug ETF (520880) and its associated off-market fund (025221) present a low-entry window, characterized by three unique advantages: purity and comprehensiveness, significant representation of leading companies, and better risk control through forced de-weighting of less liquid stocks [2] - The top ten innovative drug leaders account for over 73% of the index, highlighting the strength of the innovative drug sector [2] - The focus for 2026 will likely remain on "innovation + internationalization," with an emphasis on innovative drugs that show positive industry trends and increasing global competitiveness [1][2]